You'll need this too:

Anti-cdc2 (p34) (RABBIT) Antibody - 100-401-160

Anti-CDC20 (fizzy) (C-terminal specific) [RABBIT) Antibody - 100-401-A17

Anti-cdc2 (p34) (MOUSE) Monoclonal Antibody - 200-301-160

Anti-Aurora B (pan reactive) (RABBIT) Antibody - 600-401-465

Primary Antibodies > Phospho Specific Antibodies

Plk1 phospho T210 Antibody

Rabbit Polyclonal

Affinity Purified Plk1 pT210 was used at a 1:200 dilution to detect Plk1 by immunohistochemistry in human breast carcinoma tumor tissue. Tissue was formalin-fixed and paraffin embedded. Personal Communication, Alan Yen, LifeSpanBiosciences, Seattle, WA.

Number:

600-401-446

Size:

100 µg

Price:

$319.00

Shipping:

$20.00

Handling:

$20.00

Availability:

Ships next business day.

Datasheet
References
Reviews
Protocols
Related Products

Plk1 phospho T210 Antibody Properties

Description

Anti-Polo-like Kinase (Plk1) pT210 (RABBIT) Antibody - 600-401-446

Host

Rabbit

Target Species

Human

Known Cross Reactivity

human

Clonality

Polyclonal

Application

ELISA : 1:3,000 - 1:12,000
Western Blot : 1:200 - 1:2,000
Immunohistochemistry: 1:200 - 1:1,000
Other Dilution: User Optimized

Physical State

Liquid (sterile filtered)

Shipping Condition

Dry Ice

Format

IgG

Label

Unconjugated

Concentration

1.0 mg/mL by UV absorbance at 280 nm

Buffer

0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2

Preservative

0.01% (w/v) Sodium Azide

Stabilizer

None

GeneName

PLK1

Plk1 phospho T210 Antibody Description

Background

Polo-like Kinase pT210 Antibody detects phosphorylated Plk1 protein. Polo-like kinase 1, also known as Plk-1, serine-threonine protein kinase 13 and STPK13, may be required for cell division and have a role during G₁ or S phase and is associated with the phosphorylation of cyclin B₁. Phosphorylation of Plk-1 on T210 contributes to proper mitotic progression. Plk-1 has a nuclear localization and accumulates to a maximum during the G₂ and M phases, declines to a nearly undetectable level following mitosis and throughout G₁ phase, and then begins to accumulate again during S phase. Plk-1 is a member of the Ser/Thr protein kinase family and the CDC5/Polo subfamily and contains 2 POLO box domains.

Synonyms

PLK 1 antibody, PLK antibody, polio like kinase antibody, Polo like kinase 1 antibody, Polo-like kinase 1 antibody, Serine/threonine protein kinase 13 antibody

Immunogen

Anti-Polo-like Kinase pT210 Antibody was produced by repeated immunizations with a synthetic phospho peptide corresponding to aa 205-214 of Human Polo-like kinase 1 (Plk1) protein.

Immunogen Type

Peptide

Post Translational Modification

Phosphorylation

Storage Condition

Store vial at -20° C prior to opening. Aliquot contents and freeze at -20° C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.

Application Note

This affinity-purified antibody has been tested for use in ELISA, IHC and by western blot. Specific conditions for reactivity should be optimized by the end user. Expect a band approximately 68 kDa in size corresponding to Plk-1 by western blotting in the appropriate cell lysate or extract. This antibody is positive by IHC on kidney, liver, cancer, thyroid and lymphocyte tissue.

Purity/Specifity

Anti-Polo-like Kinase pT210 Antibody is directed against human phosphorylated Plk1 protein. This antibody was affinity purified. This antibody is specific for phosphorylated human Plk-1 protein at the pT210 residue. BLAST analysis indicates 100 % homology of the immunizing sequence with Plk-1 homologues from human, chimpanzee, pig, chicken, mouse, rat, Xenopus, dog, mosquito, zebra fish, starfish, sea urchin and fruit fly. Cross reactivity with Plk-1 protein homologues from C.elgans and honeybee may also occur as sequence homology varies by one amino acid residue in this sequence. Reactivity with Plk-1 protein from other sources is not known. Minimal reactivity is expected with the non-phosphorylated form of the protein.

Disclaimer Note-General

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.

General Reference

van Vugt,M.A., Br and Medema,R.H. (2004) Polo-like kinase-1 controls recovery from a G2 DNA damage-induced arrest in mammalian cells. Mol. Cell 15 (5), 799-811. van Vugt,M.A. et al. (2004) Polo-like kinase-1 is required for bipolar spindle formation but is dispensable for anaphase promoting complex/Cdc20 activation and initiation of cytokinesis. J. Biol. Chem. 279 (35), 36841-36854. Weichert,W., Schmidt,M., Gekeler,V., Denkert,C., Stephan,C., Jung,K., Loening,S., Dietel,M. and Kristiansen,G. (2004) Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. Prostate 60 (3), 240-245. Gunawardena,R.W., Siddiqui,H., Solomon,D.A., Mayhew,C.N., Held,J., Angus,S.P. and Knudsen,E.S. (2004) Hierarchical requirement of SWI/SNF in retinoblastoma tumor suppressor-mediated repression of Plk1. J. Biol. Chem. 279 (28), 29278-29285. Ando,K., Ozaki,T., Yamamoto,H., Furuya,K., Hosoda,M., Hayashi,S., Fukuzawa,M. and Nakagawara,A. (2004) Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation. J. Biol. Chem. 279 (24), 25549-25561. Litvak,V., Argov,R., Dahan,N., Ramachandran,S., Amarilio,R., Shainskaya,A. and Lev,S. (2004) Mitotic phosphorylation of the peripheral Golgi protein Nir2 by Cdk1 provides a docking mechanism for Plk1 and affects cytokinesis completion. Mol. Cell 14 (3), 319-330.